Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2024-03-20 00:00:00 ET · period of report 2024-03-18 · accession 0000919574-24-002115 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2024-03-20 | 2024-03-18 | LAB | Casdin Partners GP, LLC | Dir, 10% | A - Grant | $2.75 | +46.47M | 13.94M | New | +$127.78M |
| DMI | 2024-03-20 | 2024-03-18 | LAB | Casdin Partners GP, LLC | Dir, 10% | D - Sale to Iss | $2.75 | -127.8K | 0 | -100% | -$351.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-18 | A | A | 32,525,821 | $2.75 | 44,023,749 | I See footnote | — | — | (F1) The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| 2 | Common | Common Stock | 2024-03-18 | A | A | 13,939,637 | $2.75 | 13,939,637 | I See footnote | — | — | (F2) The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. |
| 3 | Derivative | Series B-1 Convertible Preferred Stock | 2024-03-18 | D | D | 89,446 | $2.75 | 0 | I See footnote | $2.75 · — to — | 32,525,821 Common Stock | (F1) The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. (F7) Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. |
| 4 | Derivative | Series B-1 Convertible Preferred Stock | 2024-03-18 | D | D | 38,334 | $2.75 | 0 | I See footnote | $2.75 · — to — | 13,939,637 Common Stock | (F2) The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. (F7) Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. |